SCHEDULE 13G/A: Cadrenal Therapeutics Insider John Raymond Murphy Updates Stake to 2.96%

John Raymond Murphy, an insider at Cadrenal Therapeutics, Inc., has filed an amended Schedule 13G, disclosing beneficial ownership of 2.96% of the company's common stock as of December 31, 2024.

Summary

• John Raymond Murphy, an individual, filed an Amendment No. 2 to Schedule 13G regarding his beneficial ownership in Cadrenal Therapeutics, Inc.
• As of December 31, 2024, Mr. Murphy beneficially owns 53,205 shares of Cadrenal Therapeutics, Inc. Common Stock.
• This ownership represents 2.96% of the company's total outstanding Common Stock.
• The total outstanding shares of Common Stock used for calculation were 1,782,486 as of December 31, 2024.
• Mr. Murphy's beneficial ownership includes 40,986 shares of Common Stock directly owned and 12,219 shares issuable upon the exercise of options within 60 days.
• Mr. Murphy holds sole voting and sole dispositive power over all 53,205 beneficially owned shares.
• The filing certifies that the securities were not acquired or held for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: The document is a factual, routine regulatory filing disclosing beneficial ownership and does not contain information that would significantly alter sentiment.

Positives

• An insider, John Raymond Murphy, maintains a beneficial ownership stake of 2.96% in Cadrenal Therapeutics, Inc., which can signal alignment of interests with shareholders.
• The filing confirms that the shares are not held for the purpose of changing or influencing control of the issuer, indicating stability in corporate governance.

Negatives

• No specific negative information is disclosed in this beneficial ownership filing.

Risks

• This Schedule 13G filing is a disclosure of beneficial ownership and does not contain information regarding company-specific risks.

Future Outlook

This Schedule 13G filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding the company's future outlook.

Management Comments

• The filing includes a certification by John Raymond Murphy stating that, to the best of his knowledge and belief, the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

This filing is a routine regulatory disclosure of an insider's ownership stake and does not provide information related to broader industry trends or competitor analysis.

Comparison to Industry Standards

• This document is a standard beneficial ownership disclosure (Schedule 13G) and does not contain information that allows for a comparison of company results to global benchmarks or specific comparable companies/projects.

Stakeholder Impact

• Provides transparency to shareholders and the market regarding an insider's ownership stake in the company.

Next Steps

• This Schedule 13G filing does not outline any specific future actions, events, or milestones for the company or the reporting person beyond the regulatory disclosure itself.

Key Dates

Keywords

Cadrenal Therapeutics, John Raymond Murphy, Schedule 13G, beneficial ownership, insider holding, common stock, equity stake